Combination regimen of epirubicin, vinorelbine and 5-fluorouracil continuous infusion as first-line chemotherapy in anthracycline-naive metastatic breast cancer patients.

[1]  D. Dodwell,et al.  Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study , 2004, British Journal of Cancer.

[2]  J. Witjes,et al.  A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life , 2003, World Journal of Urology.

[3]  G. Hortobagyi,et al.  Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Krzakowski,et al.  Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  O. Garrone,et al.  Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma , 2003, Cancer.

[6]  M. Piccart,et al.  Chemotherapy for metastatic breast cancer-report of a European expert panel. , 2002, The Lancet. Oncology.

[7]  M. Valerio,et al.  First-line treatment with epirubicin and vinorelbine in metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Ellis,et al.  A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  C. la Vecchia,et al.  Cancer Mortality in Italy, 1997: Quantifying the Fall in Rates in Women and Men , 2001, Tumori.

[10]  F. Recchia,et al.  Combined 5‐Fluorouracil Infusion With Fractionated Epirubicin and Cyclophosphamide in Advanced Breast Cancer , 2001, American journal of clinical oncology.

[11]  J. Jassem,et al.  Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Asselain,et al.  Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first‐line doxorubicin‐containing chemotherapy , 2001, Cancer.

[13]  V. Lorusso,et al.  Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Osoba,et al.  Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[16]  G. Bastert,et al.  Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis , 2000, Breast Cancer Research and Treatment.

[17]  M. Milella,et al.  Weekly epirubicin plus lonidamine in advanced breast carcinoma , 1999, Breast Cancer Research and Treatment.

[18]  S. Barni,et al.  Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  V Torri,et al.  Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B. Asselain,et al.  Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90). , 1998, British Journal of Cancer.

[21]  P. Ellis,et al.  Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  H. Gabra,et al.  Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. , 1996, British Journal of Cancer.

[23]  P. Zola,et al.  Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Lacombe,et al.  Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Talbot,et al.  Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Demicheli,et al.  Drugs ten years later: epirubicin. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[28]  V. Meininger,et al.  Biochemical effects of Navelbine on tubulin and associated proteins. , 1989, Seminars in oncology.

[29]  Terry L. Smith,et al.  Results and long term follow‐up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin‐containing chemotherapy , 1999, Cancer.

[30]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.